These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36722291)

  • 1. Utility of prognostic prediction by early assessment of response to combined treatment with nivolumab plus ipilimumab in patients with treatment-naïve metastatic renal cell carcinoma.
    Harada KI; Miyake H; Furukawa J; Fujimoto N; Fujisawa M
    Int J Urol; 2023 Sep; 30(9):798-800. PubMed ID: 36722291
    [No Abstract]   [Full Text] [Related]  

  • 2. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
    Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
    Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation.
    Schvartsman G; Carneiro APCD; Filippi RZ; Rao P; Msaouel P
    Clin Genitourin Cancer; 2019 Aug; 17(4):315-318. PubMed ID: 31213412
    [No Abstract]   [Full Text] [Related]  

  • 4. Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma.
    Kobayashi Y; Arai H; Honda M
    Curr Oncol; 2020 Aug; 27(4):225-228. PubMed ID: 32905370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
    Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S
    Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Yoshino M; Ishihara H; Nemoto Y; Nakamura K; Nishimura K; Tachibana H; Fukuda H; Toki D; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
    Jpn J Clin Oncol; 2022 Oct; 52(10):1208-1214. PubMed ID: 35780441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial Comment on "Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma".
    Teishima J
    Int J Urol; 2023 Sep; 30(9):752-753. PubMed ID: 37218357
    [No Abstract]   [Full Text] [Related]  

  • 8. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
    Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.
    Wan X; Zhang Y; Tan C; Zeng X; Peng L
    JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
    Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
    Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].
    Oya M; Tajima Y; Kabu K
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1397-1404. PubMed ID: 31530779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.
    Yamashita S; Hamamoto S; Furukawa J; Fujita K; Takahashi M; Miyake M; Ito N; Iwamoto H; Kohjimoto Y; Hara I
    Sci Rep; 2024 May; 14(1):12398. PubMed ID: 38811687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.
    Brown LC; Desai K; Wei W; Kinsey EN; Kao C; George DJ; Rini BI; Ornstein MC; Zhang T
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma.
    Bando Y; Furukawa J; Okamura Y; Hara T; Terakawa T; Nakano Y; Fujisawa M
    Anticancer Res; 2022 Feb; 42(2):973-979. PubMed ID: 35093897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma.
    Ishihara H; Kondo T; Nakamura K; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Takagi T
    Jpn J Clin Oncol; 2021 Dec; 51(12):1751-1756. PubMed ID: 34492101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab Plus Ipilimumab with Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma.
    Soulen MC; Haas NB
    J Vasc Interv Radiol; 2023 Jun; 34(6):1089-1091.e1. PubMed ID: 36804297
    [No Abstract]   [Full Text] [Related]  

  • 18. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
    Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma].
    Rexer H; Steiner T; Bergmann L
    Urologe A; 2017 Jun; 56(6):802-803. PubMed ID: 28536740
    [No Abstract]   [Full Text] [Related]  

  • 20. [Deep and Durable Response After Discontinuation of Nivolumab/Ipilimumab Combination Therapy for Metastatic Renal Cell Carcinoma : A Case Report].
    Tsuruta M; Shibasaki N; Iguch R; Yamaguchi T; Ota H; Fuchigami Y; Magaribuchi T; Naito H; Terai A
    Hinyokika Kiyo; 2020 Dec; 66(12):443-448. PubMed ID: 33435655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.